Lipid-lowering Effect of Compound Seabuckthorn Concentrate on Hyperlipidemic Rats

Objective: To explore the lipid-lowering effect of compound seabuckthorn concentrate in hyperlipidemia model rats. Methods: Sixty Wistar rats were randomly divided into blank-control group, high-fat diet group, positive control group (lovastatin capsules 1.80 mg/kg·bw), compound seabuckthorn concentrate low (3.57 mL/kg·bw), medium (7.14 mL/kg·bw), high (14.28 mL/kg·bw) dose groups. The hyperlipidemia rat models were established by feeding high-fat diet. The blank-control group and the high-fat diet group were given the same amount of normal saline by gavage, and the rats of experimental groups were given the corresponding dose of compound seabuckthorn concentrate and lovastatin suspension by gavage, respectively. After 28 days of administration, the body weight, Lee's index, serum lipid level, antioxidant level, liver index and liver pathological morphology of rats in each group were observed and analyzed. Results: Compared with the blank-control group, the body weight and Lee's index of the high-fat diet group were significantly increased (P<0.01), indicating that the models were successfully constructed. The contents of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and malondialdehyde (MDA) in serum of the positive control group and the compound seabuckthorn concentrate high dose group were lower than those of the high-fat diet group, while the contents of high-density lipoprotein cholesterol (HDL-C) and superoxide dismutase (SOD) were significantly increased (P<0.01, P<0.05). The degree of liver swelling was relatively decreased in each experimental group. Fat vacuoles were also significantly reduced in the cytoplasm. Conclusion: Compound seabuckthorn concentrate can improve the lipid level of hyperlipidemia rats and have antioxidant and liver protection effects.